Holen Sie sich die Stockscreener-App
57.82
0.04%
-0.06
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BMY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Bristol Myers Squibb Co Aktie (BMY) Neueste Nachrichten
John G Ullman & Associates Inc. Decreases Stake in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Is Bristol Myers Squibb Stock a Buy? - The Motley Fool
Primecap Management Co. CA Has $1.21 Billion Stock Holdings in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Commerce Bank Sells 30,241 Shares of Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
77,494 Shares in Bristol-Myers Squibb (NYSE:BMY) Acquired by B. Metzler seel. Sohn & Co. Holding AG - MarketBeat
Vital Signs: Merck maps Keytruda's next act in the injectables marketplace - FirstWord Pharma
Psoriasis Market is expected to rise at a significant CAGR, DelveInsight | Hangzhou Highlightll Pharmaceutical Co., Ltd, Biohaven Pharmaceuticals, Inc., SFA Therapeutics, Bristol-Myers Squibb - Barchart
Bristol Myers Squibb Co. stock underperforms Wednesday when compared to competitors - MarketWatch
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Premier Fund Managers Ltd Takes Position in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
CAMZYOS™ Honoured with the Prix Galien Canada Innovative Product Award - cnhinews.com
GLP-1 Analogues Market Outlook: Rapid Growth at 21.3% CAGR to Surpass USD 322.85 Billion by 2034 | PMR - GlobeNewswire Inc.
BRISTOL-MYERS SQUIBB CANADA WINS THE 2024 PRIX GALIEN INNOVATIVE PRODUCT AWARD - Barchart
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - MarketWatch
J&J, Protagonist's oral psoriasis prospect scores in phase 3 pair, readying case against BMS' Sotyktu - Fierce Biotech
Bristol-Myers Squibb (NYSE:BMY) Shares Sold by PNC Financial Services Group Inc. - MarketBeat
BMS CFO backs “resilient” pharma industry amid RFK’s impending governance - Pharmaceutical Technology
OneAscent Financial Services LLC Purchases Shares of 8,855 Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Why Bristol Myers Squibb is a Top 25 Dividend Giant (BMY) - Nasdaq
Bristol Myers to Present 90+ Studies at ASH, Including 5-Year Breyanzi Data | BMY Stock News - StockTitan
Bristol-Myers Squibb (NYSE:BMY) Shares Purchased by Natixis Advisors LLC - MarketBeat
Encouraging Early Data From Next-Gen Study Puts Bristol Myers' CAR T Therapy In The Spotlight For Autoimmune Diseases - Benzinga
Is Bristol-Myers Squibb Company (BMY) the Best Immunotherapy Stock to Buy Now? - Insider Monkey
EMA’s CHMP to approve BMS’ Opdivo for colorectal cancer - Pharmaceutical Technology
Bristol-Myers Squibb: Buy This Bargain Stock Before It's Gone (NYSE:BMY) - Seeking Alpha
Swiss National Bank Boosts Position in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Kinsale Capital Group Inc. Purchases 18,163 Shares of Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Mizuho Markets Americas LLC Lowers Holdings in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Kentucky Retirement Systems Lowers Stake in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Bristol Myers Squibb Co. stock underperforms Friday when compared to competitors - MarketWatch
Bristol-Myers Squibb (NYSE:BMY) Trading Down 3%Here's Why - MarketBeat
Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer - BioSpace
Bristol-Myers Faces Renewed $6.7 Billion Lawsuit Over Drug Approval Delays Amid Resolved Trustee Issue - Benzinga
EU regulators endorse meds from BMS, J&J, Eisai and more—plus a clutch of biosims - FiercePharma
Bristol-Myers Squibb (NYSE:BMY) Shares Bought by Sheaff Brock Investment Advisors LLC - MarketBeat
BMYBristol-Myers Squibb Co. Latest Stock News & Market Updates - StockTitan
Cornercap Investment Counsel Inc. Reduces Holdings in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Bristol-Myers Squibb (NYSE:BMY) Now Covered by Analysts at Wolfe Research - MarketBeat
Celgene Shareholders Hit BMS with Fresh Lawsuit for Allegedly Dodging CVR Payments - BioSpace
Bristol Myers' Cancer Drug Repotrectinib Gains Key EU Panel Backing for Lung Cancer | BMY Stock News - StockTitan
The Bristol Myers Squibb Foundation - Bristol Myers Squibb
Bristol Myers faces renewed, $6.7 billion lawsuit over delayed cancer drug - MSN
Bristol Myers faces renewed, $6.7 bln lawsuit over delayed cancer drug - Reuters
Justice on the Move: The Impact of Bristol-Myers Squibb on FLSA Forum-Shopping - The National Law Review
9,269 Shares in Bristol-Myers Squibb (NYSE:BMY) Bought by Sargent Investment Group LLC - MarketBeat
Bristol-Myers Squibb Company's (NYSE:BMY) high institutional ownership speaks for itself as stock continues to impress, up 5.7% over last week - Yahoo Finance
Bristol-Myers Squibb (NYSE:BMY) Stake Lessened by KBC Group NV - MarketBeat
Plato Investment Management Ltd Purchases 13,447 Shares of Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Clinical trials & studies - Bristol Myers Squibb
Bristol Myers Squibb showcases cardiovascular portfolio at AHA Scientific Sessions 2024 - Indian Pharma Post
ICICI Prudential Asset Management Co Ltd Sells 38,500 Shares of Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Is Bristol-Myers Squibb Company (BMY) Among The Top Dividend Contenders Right Now? - Insider Monkey
Oppenheimer & Co. Inc. Raises Position in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
BMS, Merck, Amgen and more must look to M&A to offset looming patent lapses: Leerink - FiercePharma
Pinnacle Financial Partners Inc Acquires 272,439 Shares of Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Mengis Capital Management Inc. Has $3.37 Million Stock Position in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Aigen Investment Management LP Sells 102,823 Shares of Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Equities Analysts Issue Forecasts for BMY Q4 Earnings - MarketBeat
Bristol-Myers Squibb (NYSE:BMY) Upgraded by Leerink Partnrs to "Strong-Buy" Rating - MarketBeat
Bristol Myers Squibb Co. stock outperforms competitors despite losses on the day - MarketWatch
Bristol-Myers Squibb (NYSE:BMY) Price Target Raised to $60.00 at Citigroup - MarketBeat
This Bristol-Myers Squibb Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday - Benzinga
Bristol-Myers Squibb's $14 Billion PotentialAnalyst Upgrades Stock - Benzinga
BMO Capital Markets Boosts Bristol-Myers Squibb (NYSE:BMY) Price Target to $61.00 - MarketBeat
AbbVie’s loss is Bristol Myers Squibb’s gainanalyst - Proactive Investors USA
American Assets Inc. Purchases New Holdings in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
0.22%
1.40%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):